| Autor: |
Cochrane, Tara, Enrico, Alicia, Gomez-Almaguer, David, Hadjiev, Evgueniy, Lech-Maranda, Ewa, Masszi, Tamas, Nikitin, Eugene, Robak, Tadeusz, Weinkove, Robert, Wu, Shang-Ju, Manzoor, Beenish S., Busman, Todd, Pai, Madhavi, Komlosi, Viktor, Anderson, Mary Ann |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Nov2024, Vol. 65 Issue 11, p1743-1746, 4p |
| Abstrakt: |
The letter to the editor discusses the results of the VENICE-II trial, which evaluated the impact of venetoclax monotherapy on health-related quality of life (HRQoL) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The trial showed significant improvements in HRQoL, with sustained benefits observed up to week 108. Venetoclax treatment also demonstrated positive outcomes in terms of response rates, duration of response, and overall survival. The safety profile of venetoclax remained consistent throughout the trial, with no new safety signals identified. The study emphasizes the importance of considering patient-centric factors, such as HRQoL, in CLL treatment decisions, especially in the context of evolving treatment options and long-term outcomes. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
